Chemistry & Immunochemistry of Exosporium Carbohydrates

化学

基本信息

  • 批准号:
    6832744
  • 负责人:
  • 金额:
    $ 29.91万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-05-01 至 2009-04-30
  • 项目状态:
    已结题

项目摘要

Components of the outermost surface layer of the B. anthracis spore, called the exosporium, are first to come in contact with the host, and their interactions with host defenses are likely to have an important influence on the fate of ingested spores. A major component of the exosporium is a glycoprotein called BclA. It contains about 70 PTG tripeptide repeats, several of which possess tetrasaccharide side chains composed of a unique substituted amino sugar and three rhamnose residues. The role(s) of BclA in anthrax pathogenesis has not been established but other rhamnose-containing glycoeonjugates have been found to possess a variety of potent biological activities, including activation of macrophages and inhibition of neutrophil phagocytosis. The first specific aim of this proposal is to identify the precise positions in the protein backbone of BclA that are glycosylated and also to determine the extent of substitution at the various sites. This task is complicated by the fact that the amino acid sequence of BclA is not amenable to the preparation of glycopeptide fragments and novel molecular genetic approaches will be used to locate the glycosylation sites. The second specific aim is to identify the genes involved in the assembly of the rhamnose-containing tetrasaccharides of BclA. These genes will be identified by systematically mutationally inactivating candidate genes selected on the basis of either their putative assignment in the B. anthracis genome or their similarity to known genes in other bacterial species. The effects of mutating these genes on spore morphology, viability, germination, infectivity, and virulence will be determined. The effects of the mutations on oligosaccharide structure will be studied using a variety of chemical and physical methods, including mass spectrometry and NMR methods. The third specific aim is to prepare and evaluate a novel oligosaccharide-protein conjugate vaccine in which the tetrasaccharide side chains of BclA are covalently linked to recombinant protective antigen of B. anthracis. Antibodies elicited by the vaccine should promote the phagocytosis and killing of anthrax spores as well as protect against toxemia. In one group of experiments the vaccine will be administered to mice subcutaneously using an aluminum hydroxide adjuvant. In other experiments it will be administered intranasally with a cholera toxin adjuvant in order to elicit a mucosal immune response. In both cases the ability of the vaccines to protect a susceptible strain of mice from a lethal inhalational anthrax infection will be assessed.
炭疽芽孢杆菌孢子最外层的组成部分,称为外孢子,首先与宿主接触,它们与宿主防御的相互作用可能对摄入孢子的命运有重要影响。外孢子的主要成分是一种叫做BclA的糖蛋白。它含有大约70个PTG三肽重复序列,其中一些具有由一个独特的取代氨基糖和三个鼠李糖残基组成的四糖侧链。BclA在炭疽发病机制中的作用尚未确定,但其他含鼠李糖的糖缀合物已被发现具有多种

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID G PRITCHARD其他文献

DAVID G PRITCHARD的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID G PRITCHARD', 18)}}的其他基金

B. anthracis Peptidoglycan Deacetylase as a Drug Target
B. 炭疽肽聚糖脱乙酰酶作为药物靶点
  • 批准号:
    6916423
  • 财政年份:
    2004
  • 资助金额:
    $ 29.91万
  • 项目类别:
B. anthracis Peptidoglycan Deacetylase as a Drug Target
B. 炭疽肽聚糖脱乙酰酶作为药物靶点
  • 批准号:
    6820763
  • 财政年份:
    2004
  • 资助金额:
    $ 29.91万
  • 项目类别:
Inhibition of GBS Carriage by Engineered Lactobacilli
工程乳酸杆菌抑制 GBS 携带
  • 批准号:
    6606360
  • 财政年份:
    2003
  • 资助金额:
    $ 29.91万
  • 项目类别:
Inhibition of GBS Carriage by Engineered Lactobacilli
工程乳酸杆菌抑制 GBS 携带
  • 批准号:
    6699312
  • 财政年份:
    2003
  • 资助金额:
    $ 29.91万
  • 项目类别:
BIOCHEMICAL CHARACTERIZATION OF GBS HYALURONATE LYASE
GBS 透明质酸裂解酶的生化特征
  • 批准号:
    2887507
  • 财政年份:
    1997
  • 资助金额:
    $ 29.91万
  • 项目类别:
BIOCHEMICAL CHARACTERIZATION OF GBS HYALURONATE LYASE
GBS 透明质酸裂解酶的生化特征
  • 批准号:
    2673048
  • 财政年份:
    1997
  • 资助金额:
    $ 29.91万
  • 项目类别:
BIOCHEMICAL CHARACTERIZATION OF GBS HYALURONATE LYASE
GBS 透明质酸裂解酶的生化特征
  • 批准号:
    2382616
  • 财政年份:
    1997
  • 资助金额:
    $ 29.91万
  • 项目类别:
PHASE VARIATION IN THE PATHOGENESIS OF GBS INFECTION
GBS 感染发病机制的阶段变化
  • 批准号:
    3145708
  • 财政年份:
    1992
  • 资助金额:
    $ 29.91万
  • 项目类别:
PHASE VARIATION IN THE PATHOGENESIS OF GBS INFECTION
GBS 感染发病机制的阶段变化
  • 批准号:
    2065800
  • 财政年份:
    1992
  • 资助金额:
    $ 29.91万
  • 项目类别:
PHASE VARIATION IN THE PATHOGENESIS OF GBS INFECTION
GBS 感染发病机制的阶段变化
  • 批准号:
    3145709
  • 财政年份:
    1992
  • 资助金额:
    $ 29.91万
  • 项目类别:

相似海外基金

Facility Management, Maintenance and Operations Core
设施管理、维护和运营核心
  • 批准号:
    10793949
  • 财政年份:
    2023
  • 资助金额:
    $ 29.91万
  • 项目类别:
Mechanisms of anthrax lethal toxin-induced mortality and the novel biological-based targeted therapies
炭疽致死毒素致死机制及新型生物靶向治疗
  • 批准号:
    10654406
  • 财政年份:
    2023
  • 资助金额:
    $ 29.91万
  • 项目类别:
Chemical Biology of Nitroxyl (HNO) in Bacillus Subtilis
枯草芽孢杆菌中硝酰基 (HNO) 的化学生物学
  • 批准号:
    10730746
  • 财政年份:
    2023
  • 资助金额:
    $ 29.91万
  • 项目类别:
Remyelination by intranasal TIDM peptide
鼻内 TIDM 肽进行髓鞘再生
  • 批准号:
    10582863
  • 财政年份:
    2023
  • 资助金额:
    $ 29.91万
  • 项目类别:
How is climate change driving the re-emergence and evolution of anthrax
气候变化如何推动炭疽病的重新出现和进化
  • 批准号:
    2887605
  • 财政年份:
    2023
  • 资助金额:
    $ 29.91万
  • 项目类别:
    Studentship
Development of a novel anthrax vaccine utilizing capsule biosynthesis protein CapA of Bacillus anthracis
利用炭疽杆菌荚膜生物合成蛋白CapA开发新型炭疽疫苗
  • 批准号:
    23K19460
  • 财政年份:
    2023
  • 资助金额:
    $ 29.91万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Multiscale Modeling of B. Anthracis Surface Layer Assembly and Depolymerization by Nanobodies
纳米抗体对炭疽杆菌表面层组装和解聚的多尺度建模
  • 批准号:
    10432488
  • 财政年份:
    2022
  • 资助金额:
    $ 29.91万
  • 项目类别:
Vaccine and Treatment Evaluation Units
疫苗和治疗评估单位
  • 批准号:
    10493533
  • 财政年份:
    2022
  • 资助金额:
    $ 29.91万
  • 项目类别:
Metal requirement and mechanism of anthrax lethal factor and other zinc proteases
炭疽致死因子和其他锌蛋白酶的金属需求和机制
  • 批准号:
    RGPIN-2018-06496
  • 财政年份:
    2022
  • 资助金额:
    $ 29.91万
  • 项目类别:
    Discovery Grants Program - Individual
Functional requirement of CMG2 for endothelial cell chemotaxis and resulting angiogenesis
CMG2 内皮细胞趋化性和由此产生的血管生成的功能要求
  • 批准号:
    10522258
  • 财政年份:
    2022
  • 资助金额:
    $ 29.91万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了